Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
The use of an aromatase inhibitor (AI) in combination with ovarian function suppression (OFS) has become the mainstay of adjuvant endocrine therapy in high-risk premenopausal patients with hormone receptor-positive breast cancer. Although five years of such therapy effectively reduces recurrence rat...
Main Authors: | Giuseppe Buono, Grazia Arpino, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Fabio Puglisi, Alberto Zambelli, Saverio Cinieri, Francesco Nuzzo, Vincenzo Di Lauro, Paolo Vigneri, Giampaolo Bianchini, Filippo Montemurro, Alessandra Gennari, Michelino De Laurentiis |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1032166/full |
Similar Items
-
An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
by: Giacomo Pelizzari, et al.
Published: (2018-09-01) -
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
by: Alessandra Fabi, et al.
Published: (2022-09-01) -
Premenopausal osteoporosis
by: Marilyn Lee Cheng, et al.
Published: (2013-01-01) -
G Gejala Menopause pada Wanita Premenopause
by: MK. Fitriani Fruitasari
Published: (2024-06-01) -
Does Diet Offset the Effect of Veiling on Bone Mineral Density of premenopausal Indian women
by: Seema Kapoor, et al.
Published: (2015-01-01)